-
Survey: 76% of providers, prescribers say proposed generic drug label rule would confuse patients
WASHINGTON — A survey co-released Wednesday by the Generic Pharmaceutical Association and the National Coalition on Healthcare reveals that 8-in-10 healthcare providers have serious concerns about a proposed Food and Drug Administration rule on generic drug labeling.
A random phone survey of 150 physicians, 150 physician assistants and 150 pharmacists conducted by Fairleigh Dickinson University’s PublicMind on behalf of GPhA, found strong reservations about many of the rule’s key provisions among all three groups.
-
FDA approves Lannett's codeine sulfate tablets
PHILADELPHIA — Lannett Co. received approval from the Food and Drug Administration for codeine sulfate tablets USP, a schedule II controlled substance, in 15 mg, 30 mg and 60 mg dosage strengths. It is the equivalent to codeine sulfate tablets USP 15 mg, 30 mg and 60 mg, from Roxane Labs.